Gainers
- TCR2 Therapeutics TCRR shares rose 7.0% to $3.83 during Thursday's after-market session. The company's market cap stands at $146.3 million.
- Star Equity Hldgs STRR shares increased by 5.88% to $1.44. This security traded at a volume of 77.2K shares come close, making up 43.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $8.3 million.
- Athersys ATHX shares moved upwards by 5.0% to $0.88. The market value of their outstanding shares is at $205.9 million.
- Acorda Therapeutics ACOR stock rose 4.66% to $2.02. The market value of their outstanding shares is at $22.6 million.
- Taysha Gene Therapies TSHA stock rose 4.65% to $8.55. The company's market cap stands at $328.9 million.
- Evofem Biosciences EVFM stock increased by 4.62% to $0.45. The market value of their outstanding shares is at $73.1 million.
Losers
- Vyant Bio VYNT stock decreased by 5.4% to $1.22 during Thursday's after-market session. The company's market cap stands at $35.3 million.
- Aptorum Group APM shares decreased by 4.15% to $1.62. Aptorum Group's trading volume hit 311.9K shares by close, accounting for 241.2% of its average volume over the last 100 days. The company's market cap stands at $57.7 million.
- Cerus CERS shares fell 3.91% to $5.17. This security traded at a volume of 150.1K shares come close, making up 10.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $890.6 million.
- PolarityTE PTE stock decreased by 3.83% to $0.59. The company's market cap stands at $47.9 million.
- Artelo Biosciences ARTL stock fell 3.56% to $0.41. The market value of their outstanding shares is at $17.3 million.
- Freeline Therapeutics FRLN shares fell 3.54% to $1.36. The market value of their outstanding shares is at $48.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.